The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Biodesix; Genentech; Ignyta; Paradigm; Takeda
 
Research Funding - Boston Biomedical (Inst); Merck (Inst); Pharmacyclics (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Daiichi Sankyo; Foundation Medicine
Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Eisai; Eisai; G1 Therapeutics; Lilly; MedImmune; Novartis; Sandoz; Seagen; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
 
Kyriakos P. Papadopoulos
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Genmab (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tarveda Therapeutics (Inst)
 
Marta Gil Martin
No Relationships to Disclose
 
Victor Moreno
No Relationships to Disclose
 
April K.S. Salama
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Abbvie (I); Bristol-Myers Squibb (Inst); Celldex (Inst); Dynavax Technologies (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); Reata Pharmaceuticals (Inst)
 
Emiliano Calvo
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Celgene; Cerulean Pharma; EUSA Pharma; Janssen-Cilag; Nanobiotix; Novartis; Pierre Fabre; PsiOxus Therapeutics; Seagen
Speakers' Bureau - Novartis
Research Funding - Abbvie; Amcure; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; H3 Biomedicine; Incyte; Janssen Oncology; Kura Oncology; Lilly; Loxo; Macrogenics; Menarini; Merck; Merck Serono; Merus; Millennium; Nanobiotix; Nektar; Novartis; Pfizer; PharmaMar; Principa Biopharma; PsiOxus Therapeutics; Puma Biotechnology; RigonTEC; Roche/Genentech; Sanofi; Synthon; Taiho Pharmaceutical; Tesaro
Travel, Accommodations, Expenses - Celgene; Novartis
 
Nelson S Yee
No Relationships to Disclose
 
Howard Safran
No Relationships to Disclose
 
Antonio González-Martín
Consulting or Advisory Role - AstraZeneca; PharmaMar; Roche; Tesaro
Speakers' Bureau - AstraZeneca; PharmaMar; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Tesaro
 
Raid Aljumaily
No Relationships to Disclose
 
Daruka Mahadevan
Speakers' Bureau - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Jiaxin Niu
No Relationships to Disclose
 
Kosalai Kal Mohan
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Jingjin Li
Employment - Novartis; Regeneron
Stock and Other Ownership Interests - Novartis; Regeneron
 
Elizabeth Stankevich
Employment - Regeneron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene; Merck; Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Consulting or Advisory Role - Egenix
Research Funding - AstraZeneca/MedImmune; Novartis; Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron (I)
 
Hani M. Babiker
Consulting or Advisory Role - Celgene; Endocyte